Results 161 to 170 of about 15,966 (204)

Intravenous Lidocaine for Postoperative Pain and Recovery After Robotic Prostate Adenomectomy: A Retrospective Observational Cohort Study. [PDF]

Medicina (Kaunas)
Popa GM, Abu-Awwad SA, Abu-Awwad A, Marta CI, Bimbo-Szuhai E, Bontea MG, Osiceanu AG, Bina AM, Cezar CMM, Puscas CD, Botea MO.   +10 more
europepmc   +1 more source

Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer

BJU International, Volume 137, Issue 2, Page 339-347, February 2026.
Objective To report long‐term oncological outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) undergoing bladder‐sparing therapy (BST) after bacillus Calmette–Guérin (BCG) failure. Patients and Methods We retrospectively reviewed patients with HR‐NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure,
Ian M. McElree, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Vignesh T. Packiam, Michael A. O'Donnell   +5 more
wiley   +1 more source

First Brazilian Series of Urologic Surgeries Using Versius Robotic Multiport Platform. [PDF]

Int Braz J Urol
Almeida GL, Busato WFS, Berger AK, Codagnone V, Winter G, Kinchescki R, Santos PC, Leães LM, Pérès YP, Gobbi D, Paludo AO, Burttet LM, Pugliesi FG, Guimarães GC, Schroeder G, Bastian AJ, Piovesan LF, Berger M, da Silva RK, Kaminagakura FG.   +19 more
europepmc   +1 more source

Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer

BJU International, Volume 137, Issue 2, Page 360-367, February 2026.
Objectives To develop a drug‐releasing intravesical floating technology (DRIFT) device for controlled sequential delivery of gemcitabine and docetaxel (Gem/Doce) to optimise the treatment of non‐muscle‐invasive bladder cancer (NMIBC) while enabling patient mobility and self‐removal, as sequential intravesical Gem/Doce has been increasingly utilised but
Ashley C. Rhodes, Kaitlyn A. McClintic, Emily Witt, Ikenna Nwosu, Kyle R. Balk, Colin Reis, Ian C. Sutton, Jianling Bi, Melinda Z. Fu, Michael A. O’Donnell, Vignesh T. Packiam, James D. Byrne   +11 more
wiley   +1 more source

Cost Considerations in Penile Implantation Revision Surgery from a Global Perspective. [PDF]

Curr Urol Rep
Majzoub A.
europepmc   +1 more source

Urologic chronic pelvic pain syndrome 3‐year symptom trajectories: the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study

BJU International, Volume 137, Issue 2, Page 312-322, February 2026.
Objectives To characterise 3‐year pelvic pain and urinary symptom trajectories and to identify baseline factors associated with urologic chronic pelvic pain syndrome (UCPPS) improvement. Patients and Methods The Trans‐Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Symptom Patterns Study was a multicentre, prospective cohort study
Catherine S. Bradley, Mengying You, Wensheng Guo, Niloofar Afari, Priyanka Gupta, Karl J. Kreder, John N. Krieger, H. Henry Lai, Susan K. Lutgendorf, Bruce D. Naliboff, Siobhan Sutcliffe, Frank Tu, David A. Williams, Tara McWilliams, Larissa Rodriguez, J. Richard Landis, for the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network   +16 more
wiley   +1 more source

Modern approaches to BPH management: expert insights and the latest evidence from the 2024 International Functional and Reconstructive Urology Update. [PDF]

Ther Adv Urol
Hou V, Vereecken SJ, Doersch KM, Zorn KC, Pohlman GD, Lloyd GL.   +5 more
europepmc   +1 more source

Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway

Cancer Science, Volume 117, Issue 2, Page 364-376, February 2026.
BACH1 is associated with poor prognosis in BC patients and plays a critical role in promoting tumor progression and metastasis. Furthermore, we elucidated the mechanism by which BACH1 facilitates tumor progression and metastasis, primarily through activation of the EMT pathway. These findings suggest that BACH1 may serve as a novel prognostic biomarker
Tomoya Hatayama, Kenshiro Takemoto, Kohei Kobatake, Kento Miura, Liyanage P. Perera, Ryoken Yamanaka, Kazuma Yukihiro, Hiroyuki Shikuma, Kyosuke Iwane, Ryo Tasaka, Yuki Kohada, Miki Naito, Shunsuke Miyamoto, Yohei Sekino, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Osamu Kaminuma, Nobuyuki Hinata   +19 more
wiley   +1 more source

Management and Outcomes of Urinary Tract Involvement in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): A Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Karakayali F, Aktas MK, Aytac E, Sungurtekin U, Demirbas S, Oncel M, Ozturk E, Colak T, Ince M, Haksal M, Coskun S, Sokmen S.   +11 more
europepmc   +1 more source

Mixed Gonadal Dysgenesis: A Comprehensive Review of Clinical Spectrum, Diagnostic Strategies, and Management Approaches

Clinical Endocrinology, Volume 104, Issue 2, Page 92-102, February 2026.
ABSTRACT Background Mixed gonadal dysgenesis (MGD) is a rare form of differences in sex development (DSD) typically associated with 45,X/46,XY mosaicism. The phenotypic presentation of MGD varies from atypical genitalia to typical male or female appearances often associated with Turner stigmata.
Dinesh Giri, Sushil Yewale, Hannah Hickingbotham, Cara Williams, Mohamed Shalaby, Julie Alderson, Julie Park   +6 more
wiley   +1 more source